ProPhase Labs Company Top Insiders
| PRPH Stock | USD 0.52 0.10 16.13% |
ProPhase Labs employs about 96 people. The company is managed by 13 executives with a total tenure of roughly 22 years, averaging almost 1.0 years of service per executive, having 7.38 employees per reported executive. Assessment of ProPhase Labs' management performance can provide insight into the firm performance.
| Ted Karkus Chairman Chairman and CEO |
ProPhase Labs Management Team Effectiveness
The company has return on total asset (ROA) of (0.235) % which means that it has lost $0.235 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2034) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -1.05. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -1.18. As of now, ProPhase Labs' Intangible Assets are increasing as compared to previous years. The ProPhase Labs' current Other Assets is estimated to increase to about 1.6 M, while Total Assets are projected to decrease to under 36.6 M.The ProPhase Labs' current Net Income Applicable To Common Shares is estimated to increase to about 7.6 M, while Common Stock Shares Outstanding is projected to decrease to under 1.8 M.
ProPhase Labs Workforce Comparison
ProPhase Labs is regarded third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,139. ProPhase Labs holds roughly 96.0 in number of employees claiming about 8% of equities under Health Care industry.
ProPhase Labs Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProPhase Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProPhase Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ProPhase Labs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ted Karkus over a month ago Acquisition by Ted Karkus of 500000 shares of ProPhase Labs at 0.6 subject to Rule 16b-3 | ||
Ted Karkus over three months ago Acquisition by Ted Karkus of 500000 shares of ProPhase Labs at 0.6 subject to Rule 16b-3 | ||
Ted Karkus over three months ago Acquisition by Ted Karkus of 500000 shares of ProPhase Labs at 0.6 subject to Rule 16b-3 | ||
Gleckel Louis Md over six months ago Acquisition by Gleckel Louis Md of 5564 shares of ProPhase Labs at 2.02 subject to Rule 16b-3 | ||
Gleckel Louis Md over six months ago Acquisition by Gleckel Louis Md of 100000 shares of ProPhase Labs at 5.28 subject to Rule 16b-3 | ||
Hirsch Warren over six months ago Acquisition by Hirsch Warren of 40000 shares of ProPhase Labs at 7.31 subject to Rule 16b-3 | ||
Ted Karkus over six months ago Acquisition by Ted Karkus of 2300000 shares of ProPhase Labs at 3.0 subject to Rule 16b-3 | ||
Stu Hollenshead over six months ago Acquisition by Stu Hollenshead of 500000 shares of ProPhase Labs at 0.6 subject to Rule 16b-3 |
ProPhase Labs Notable Stakeholders
A ProPhase Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProPhase Labs often face trade-offs trying to please all of them. ProPhase Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProPhase Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ted Karkus | Chairman and CEO | Profile | |
| Jason Karkus | President Diagnostics | Profile | |
| Alice Lioi | EVP BioPharma | Profile | |
| Billy White | Consultant | Profile | |
| Stu Hollenshead | Chief Officer | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Kevin Quinn | Chief Genomics | Profile | |
| Lance Bisesar | Corporate Controller | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Kamal Obbad | Senior Genomics | Profile | |
| Monica Brady | Principal Financial Officer & Principal Accounting Officer | Profile | |
| Jed Latkin | Chief Department | Profile |
About ProPhase Labs Management Performance
The success or failure of an entity such as ProPhase Labs often depends on how effective the management is. ProPhase Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProPhase management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProPhase management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.11) | (1.05) | |
| Return On Capital Employed | (1.24) | (1.18) | |
| Return On Assets | (0.84) | (0.80) | |
| Return On Equity | (7.26) | (6.89) |
ProPhase Labs Workforce Analysis
Traditionally, organizations such as ProPhase Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProPhase Labs within its industry.ProPhase Labs Manpower Efficiency
Return on ProPhase Labs Manpower
| Revenue Per Employee | 70.5K | |
| Revenue Per Executive | 520.8K | |
| Net Loss Per Employee | 515.9K | |
| Net Loss Per Executive | 3.8M |
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |